Integrated Depression Care
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorUniversity Ghent
About this trial
The Integrated DEpression CAre (IDECA) Programme is a multi-faceted intervention strategy aiming to improve guideline adherence and shared care practices for depression management in both providers and patients, as measured through a set of process and clinical outcome indicators (primary outcome measure).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
persons between 18-65
presenting to the general practitioner's office
with depressive symtomatology
Disqualifiers
Severe depression warranting direct referral to specialized services
Trial design
Design model
Single group
Treatments tested in this trial
Integrated care
Other interventionThe intervention will be modelled based on the most frequently reported patient, family physician and specialist barriers in depression management. In this project, multiple interventions aiming to tackle these barriers will be set up, with the WHO Framework on Integrated People-Centred Health Services (IPCHS) serving as conceptual backbone to the study (Table 1). The IPCHS distinguishes five interdependent strategies supporting a shift in healthcare delivery, management and funding towards universal health coverage. These strategies are: 1. empowering and engaging people and communities; 2. strengthening governance and accountability; 3. reorienting the model of care; 4. coordinating services within and across sectors; 5. creating an enabling environment.
Treatment groups
150 Participants
are divided into 1 treatment groupGroup A: Integrated care armExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Intervention integration
Nomad questionnaire (4 monthly), followed by focus groups following Balint method, and individual interviews.
Time frame
14 monthsSecondary outcomes
1
Depression
PHQ-9 (Patient Health Questionnaire. DSM-5 depression), A PHQ-9 score total of 0-4 points equals "normal" or minimal depression. Scoring between 5-9 points indicates mild depression, 10-14 points indicates moderate depression, 15-19 points indicates moderately severe depression, and 20 or more points indicates severe depression
Time frame
12 months2
Depression and anxiety
OQ-45-2 (Outcome Questionnaire. Transdiagnostical instrument focused on anxiety and depression) Total Score * Total scores (≥ 64) reflect increased distress * High is anything above 105 * Moderately High is between 83 and 105 * Moderate is between 64 and 82 * Low is anything below 64 Symptom Distress (SD) * Scores (≥ 37) indicate subjective discomfort Interpersonal Relations (IR) * Scores (≥ 16) reflect problems in interpersonal relations. Social Role (SR) * Scores (≥ 13) indicate dissatisfaction, conflict, distress, and inadequacy in performance of tasks related to employment, school, family roles and leisure life.
Time frame
12 months3
Medication adherence and self-efficacy
MARS-5 (Medication adherence report score) Each item was rated on a 5-point Likert scale, and the range of the MARS-5 total score is between 5 and 25. A higher score on the MARS-5 represents better medication adherence. \<21 suboptimal adherence. MUSE (Medication Understanding and Use Self-Efficacy Scale). Score 8-32. Higher scores are better.
Time frame
12 months4
Resource use
iMCQ (The iMTA Medical Consumption Questionnaire) to capture depression-related resource use
Time frame
12 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov